203
Views
7
CrossRef citations to date
0
Altmetric
Original Article

Association of the microsatellite (GT)n repeat polymorphisms of the HO-1 gene promoter and corresponding serum levels with the risk of laryngeal squamous cell carcinoma

, , , , , & show all
Pages 806-811 | Received 20 Dec 2015, Accepted 12 Feb 2016, Published online: 24 Mar 2016

References

  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5–29.
  • Nogueira GA, Lourenço GJ, Oliveira CB, Marson FA, Lopes-Aguiar L, Costa EF, et al. Association between genetic polymorphisms in DNA mismatch repair-related genes with risk and prognosis of head and neck squamous cell carcinoma. Int J Cancer 2015;137:810–18.
  • Avila DD, D’Avila J, Góis C, Barretto L. Premalignant laryngeal lesions: twenty-year experience in specialized service. Int Arch Otorhinolaryngol 2014;18:352–6.
  • Grochot-Przeczek A, Dulak J, Jozkowicz A. Haem oxygenase-1: non-canonical roles in physiology and pathology. Clin Sci (Lond) 2012;122:93–103.
  • Was H, Dulak J, Jozkowicz A. Heme oxygenase-1 in tumor biology and therapy. Curr Drug Targets 2010;11:1551–70.
  • Vashist YK, Blessmann M, Trump F, Kalinin V, Kutup A, Schneider C, et al. Microsatellite GTn-repeat polymorphism in the promoter of heme oxygenase-1 gene is an independent predictor of tumor recurrence in male oral squamous cell carcinoma patients. J Oral Pathol Med 2008;37:480–4.
  • Yamada N, Yamaya M, Okinaga S, Nakayama K, Sekizawa K, Shibahara S, et al. Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. Am J Hum Genet 2000;66:187–95.
  • Zhang L, Song FF, Huang YB, Zheng H, Song FJ, Chen KX. Association between the (GT)n polymorphism of the HO-1 gene promoter region and cancer risk: a meta-analysis. Asian Pac J Cancer Prev 2014;15:4617–22.
  • Hu JL, Li ZY, Liu W, Zhang RG, Li GL, Wang T, et al. Polymorphism in heme oxygenase-1 (HO-1) promoter and alcohol are related to the risk of esophageal squamous cell carcinoma on Chinese males. Neoplasma 2010;57:86–92.
  • Motovali-Bashi M, Hamidy M. Association between GT-repeat polymorphism at heme oxygenase-1 gene promoter and gastric cancer and metastasis. Tumour Biol 2015;36:4757–62.
  • Vashist YK, Uzungolu G, Kutup A, Gebauer F, Koenig A, Deutsch L, et al. Heme oxygenase-1 germ line GTn promoter polymorphism is an independent prognosticator of tumor recurrence and survival in pancreatic cancer. J Surg Oncol 2011;104:305–11.
  • Okamoto I, Krögler J, Endler G, Kaufmann S, Mustafa S, Exner M, et al. A microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with risk for melanoma. Int J Cancer 2006;119:1312–15.
  • Vashist YK, Uzunoglu G, Cataldegirmen G, Kalinin V, Schurr P, Koenig AM, et al. Haeme oxygenase-1 promoter polymorphism is an independent prognostic marker of gastrointestinal stromal tumour. Histopathology 2009;54:303–8.
  • Gandini NA, Fermento ME, Salomón DG, Blasco J, Patel V, Gutkind JS, et al. Nuclear localization of heme oxygenase-1 is associated with tumor progression of head and neck squamous cell carcinomas. Exp Mol Pathol 2012;93:237–45.
  • Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med 2010;49:1603–16.
  • Karaman E, Uzun H, Papila I, Balci H, Ozdilek A, Genc H, et al. Serum paraoxonase activity and oxidative DNA damage in patients with laryngeal squamous cell carcinoma. J Craniofac Surg 2010;21:1745–9.
  • Zhang H, Song X, Liu X, Zhang Q, Sun Y, Chen X, et al. Preliminary proteomic analysis of human serum from patients with laryngeal carcinoma. Eur Arch Otorhinolaryngol 2012;269:557–63.
  • Blann AD, Balakrishnan B, Ryan P, Lip GY. Increased levels of plasma haemoxygenase-1 in prostate cancer. Prostate Cancer Prostatic Dis 2011;14:114–17.
  • Rizzo M, Abate N, Chandalia M, Rizvi AA, Giglio RV, Nikolic D, et al. Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: a prospective pilot study. J Clin Endocrinol Metab 2015;100:603–6.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.